Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309779 | 0.87 | — | — | |
| SCHEMBL12309523 | 0.85 | HTT (0.42) | KDM4EHTTHSD17B10 | |
| SCHEMBL187246 | 0.85 | KDM4E (0.47) | KDM4E | |
| SCHEMBL12309726 | 0.83 | HSD17B2 (0.45) | KDM4EHTTHSD17B10 | |
| SCHEMBL12309491 | 0.83 | MAPT (0.52) | KDM4EHTTHSD17B10P2RY12 | |
| SCHEMBL12309739 | 0.77 | KDM4E (0.45) | KDM4E | |
| SCHEMBL187474 | 0.76 | KDM4E (0.51) | KDM4E | |
| SCHEMBL187700 | 0.74 | KDM4E (0.45) | KDM4E | |
| SCHEMBL188057 | 0.73 | — | — | |
| SCHEMBL187055 | 0.73 | KDM4E (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2133332-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | KDM4E 399/4885HTT 3002/4885HSD17B10 673/4885 |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | KDM4E 399/4885HTT 3002/4885HSD17B10 673/4885 |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | KDM4E 399/4885HTT 3002/4885HSD17B10 673/4885 |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | KDM4E 399/4885HTT 3002/4885HSD17B10 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.